{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:36:59Z","timestamp":1793036219123,"version":"4.5.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is a clinically aggressive non-Hodgkin lymphoma associated with many immune disorders. The incidence of AITL has gradually increased in Asia in recent years. Malignant AITL cells originate from T follicular helper cells, which have a unique morphology and complex biological characteristics. High-throughput sequencing studies have identified many gene mutations associated with its pathogenesis, including mutations in tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase (NADP+) 2 (IDH2), DNA methyltransferase 3 alpha (DNMT3A), ras homolog family member A (RHOA), and T cell receptor-related genes. Currently, there is no standardized treatment for AITL, the first-line chemotherapy is ineffective, the recurrence rate is high, the overall prognosis of patients is poor, and the median survival time does not exceed three years. New drugs are urgently needed. However, with continuous in-depth study of the molecular genetic mechanism of AITL, some new drugs and therapies have been tested for patients with relapsed and refractory AITL, achieving some therapeutic effects. Increasing clinical studies are evaluating new potential targets for AITL based on specific molecular markers, gradually improving individualized treatment and ultimately improving the clinical prognosis of patients with AITL. This review first summarizes the progress of research on the etiology, clinical pathological characteristics, and molecular genetic mechanisms of AITL to enhance understanding of the disease. It then summarizes the progress of research on its treatment strategies to provide some references for clinically diagnosing and treating AITL.<\/jats:p>","DOI":"10.3389\/fonc.2025.1479179","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:05:27Z","timestamp":1740967527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Advancing the understanding and management of angioimmunoblastic T-cell lymphoma: insights into its pathogenesis, clinical features, and emerging therapeutic strategies"],"prefix":"10.3389","volume":"15","author":[{"given":"Yurou","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"B1","first-page":"99","article-title":"Angioimmunoblastic T-Cell Lymphoma","volume-title":"Cancer Treat Res","author":"Yabe","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-017-0657-y","article-title":"Aggressive angioimmunoblastic T cell lymphomas (AITL) with soft tissue extranodal mass varied histopathological patterns with peripheral blood, bone marrow, and splenic involvement and review of literature","volume":"9","author":"Mukherjee","year":"2018","journal-title":"Indian J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.053","article-title":"Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features","volume":"81","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2024.05.014","article-title":"Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma","volume":"101","author":"Kameoka","year":"2015","journal-title":"Int J hematology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102392","article-title":"Novel T follicular helper-like T-cell lymphoma therapies: from preclinical evaluation to clinical reality","volume":"14","author":"Krug","year":"2022","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01197-9","article-title":"Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I diagnose angioimmunoblastic T-cell lymphoma","volume":"156","author":"Xie","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.03.002","article-title":"Clinicopathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis: RHOA mutations in AITL","volume":"21","author":"Nguyen","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/path.4898","article-title":"TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma","volume":"242","author":"Schwartz","year":"2017","journal-title":"J pathology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02699-2","article-title":"DNMT3A R882H accelerates angioimmunoblastic T-cell lymphoma in mice","volume":"42","author":"Zheng","year":"2023","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood J Am Soc Hematology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17763","DOI":"10.18632\/oncotarget.14846","article-title":"Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.3324\/haematol.2015.133074","article-title":"A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"key":"B17","volume-title":"The FYN-TRAF3IP2 gene fusion drives oncogenic NF-\u03baB signaling in peripheral T cell lymphoma","author":"Kim","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA\u2013VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1746553","article-title":"Angioimmunoblastic T-cell lymphoma-like lymphadenopathy in mice transgenic for human RHOA with p. Gly17Val mutation","volume":"9","author":"Lee","year":"2020","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.celrep.2019.07.094","article-title":"Non-catalytic roles of Tet2 are essential to regulate hematopoietic stem and progenitor cell homeostasis","volume":"28","author":"Ito","year":"2019","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.83","article-title":"Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice","volume":"4","author":"Muto","year":"2014","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood J Am Soc Hematology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3610","article-title":"DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.29","article-title":"DNMT3AR882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid Malignancies in mice","volume":"30","author":"Scourzic","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood J Am Soc Hematology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3324\/haematol.2015.139253","article-title":"Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma","volume":"101","author":"Yoo","year":"2016","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s43018-020-00161-w","article-title":"FYN\u2013TRAF3IP2 induces NF-\u03baB signaling-driven peripheral T-cell lymphoma","volume":"2","author":"Moon","year":"2021","journal-title":"Nat cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell\u2013derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood J Am Soc Hematology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030702","article-title":"STAT3 mutation is associated with STAT3 activation in CD30+ ALK\u2013 ALCL","volume":"12","author":"Andersson","year":"2020","journal-title":"Cancers"},{"key":"B32","first-page":"31","article-title":"Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma","volume-title":"Cancer Treat Res","author":"Iqbal","year":"2019"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.4104.4104","article-title":"Recurrent VAV1 abnormalities in angioimmunoblastic T cell lymphoma","volume":"128","author":"Komori","year":"2016","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040610","article-title":"Comprehensive Epstein-Barr virus transcriptome by RNA-sequencing in angioimmunoblastic T cell lymphoma (AITL) and other lymphomas","volume":"13","author":"Bayda","year":"2021","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2742","article-title":"EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma","volume":"9","author":"Eladl","year":"2020","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3390\/cancers14122899","article-title":"Epstein-barr virus (EBV) is mostly latent and clonal in angioimmunoblastic T cell lymphoma (AITL)","volume":"14","author":"Bahri","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2023.05.10","article-title":"Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients","volume":"35","author":"Shi","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood J Am Soc Hematology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Advances"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S117007","article-title":"Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma","volume":"10","author":"Zhang","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12185-020-02879-w","article-title":"Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"112","author":"Yamasaki","year":"2020","journal-title":"Int J Hematology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1200\/jco.2019.37.15_suppl.7503","article-title":"First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation-final results of the AATT study","volume":"37","author":"Tournilhac","year":"2019","journal-title":"Hematological Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","article-title":"Development of new agents for peripheral T-cell lymphoma","volume":"19","author":"Ito","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8175957","DOI":"10.1155\/2016\/8175957","article-title":"Long-term treatment with romidepsin in patients with peripheral T-cell lymphoma","volume":"2016","author":"Irl\u00e9","year":"2016","journal-title":"Case Rep Hematol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.2991.2991","article-title":"A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas","volume":"128","author":"Mehta-Shah","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01780-1","article-title":"Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib\/II study","volume":"37","author":"Chiappella","year":"2023","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1430648","article-title":"Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood advances"},{"key":"B58","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.medj.2024.07.007","article-title":"A prospective phase 2 study of combination epigenetic therapy against relapsed\/refractory peripheral T cell lymphoma","volume":"5","author":"Ding","year":"2024","journal-title":"Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood J Am Soc Hematology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood J Am Soc Hematology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real-world efficacy of 5-azacytidine as salvage chemotherapy for angioimmunoblastic T-cell lymphoma","volume":"22","author":"Yoon","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood J Am Soc Hematology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018254","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood J Am Soc Hematology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood J Am Soc Hematology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220968615","article-title":"Brentuximab vedotin in real life, a seven year experience in patients with refractory\/relapsed CD30+ T cell lymphoma","volume":"27","author":"Oberic","year":"2021","journal-title":"J Oncol Pharm Practice"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008524","article-title":"Salvage therapy with brentuximab-vedotin and bendamustine for patients with R\/R PTCL: a retrospective study from the LYSA group","volume":"7","author":"Aubrais","year":"2023","journal-title":"Blood Adv"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070660","article-title":"Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials","volume":"13","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood J Am Soc Hematology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): An open-label phase I\/II trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood J Am Soc Hematology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S297539","article-title":"Promising response to lenalidomide-combination therapy in a discordant lymphoma consisting of EBV-positive diffuse large b-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report","volume":"14","author":"Hu","year":"2021","journal-title":"OncoTargets Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18281","article-title":"Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma","volume":"198","author":"Shichijo","year":"2022","journal-title":"Br J Haematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2726","article-title":"The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study","volume":"38","author":"Bingjie","year":"2020","journal-title":"Hematological Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10071","article-title":"Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen","volume":"30","author":"Chen","year":"2011","journal-title":"Chin J Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012806","article-title":"Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma","volume":"8","author":"Witzig","year":"2024","journal-title":"Blood Adv"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1388","article-title":"Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma","volume":"6","author":"Rai","year":"2018","journal-title":"Clin Case Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"haematologica"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.320","article-title":"Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas","volume":"23","author":"Feldman","year":"2009","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.7150\/jca.17358","article-title":"IRF4\/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma","volume":"8","author":"Heo","year":"2017","journal-title":"J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leukemia lymphoma"},{"key":"B83","doi-asserted-by":"publisher","first-page":"76231","DOI":"10.18632\/oncotarget.19301","article-title":"Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma","volume":"8","author":"Ham","year":"2017","journal-title":"Oncotarget"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0428","article-title":"Adherence to the WCRF\/AICR dietary recommendations for cancer prevention and risk of cancer in elderly from Europe and the United States: a meta-analysis within the CHANCES project","volume":"26","author":"Jankovic","year":"2017","journal-title":"Cancer Epidemiology Biomarkers Prev"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2015.04.001","article-title":"Regulatory role of natural killer T cells in diabetes","volume":"38","author":"Tard","year":"2015","journal-title":"Biomed J"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12169","article-title":"Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC 14a","volume":"12","author":"Kim","year":"2018","journal-title":"Mol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1300893","article-title":"Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma","volume":"58","author":"Yoon","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0069","article-title":"Health state utilities in patients with advanced non-small-cell lung cancer in China","volume":"7","author":"Shen","year":"2018","journal-title":"J Comp Effectiveness Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2955","article-title":"Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed\/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma","volume":"29","author":"Chavez","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1479179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:05:33Z","timestamp":1740967533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1479179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":90,"alternative-id":["10.3389\/fonc.2025.1479179"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1479179","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"1479179"}}